Clinical Reminder |
Cholestatic jaundice following carbimazole therapy in an elderly thyrotoxic patient
Department of Adult Medicine, Nevill Hall Hospital, Brecon Road, Abergavenny NP7 7EG, UK
* To whom correspondence should be addressed Email: nadim.haboubi{at}gwent.wales.nhs.uk
An 81-year-old lady with dyspnoea and palpitations was found to be in atrial fibrillation with a rate of 130 bpm.
She remained tachycardic despite digitalisation, and a thyroid function test revealed a low TSH (<1.0 mµ/l) and high T4 (28 µg/dl).
Carbimazole 20 mg was commenced. However, 3 weeks later, the patient became jaundiced (bilirubin 144 µmol/l, ALP 1192 iµ/l and ALT 289 iµ/l). Abdominal ultrasound, viral hepatitis titres and autoantibodies were normal.
Carbimazole was replaced by Propylthiouracil and within three days liver biochemistry began improving and two months later had normalised.
Side-effects of carbimazole include rash, pruritus and agranulocytosis [1]. Cholestasis is a rare side-effect [2]. Recent reports of cholestatic jaundice caused by sequential carbimazole and propylthiouracil suggest the possibility of crossover reactivity [3] but fortunately our patient recovered on stopping carbimazole.
Carbimazole may induce fulminant hepatitis and we suggest periodic monitoring of liver function tests because early detection of drug-induced cholestasis is required to minimise the risk of potentially fatal consequences.
| References |
|---|
|
|
|---|
- Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf 1996; 15: 5363.[Web of Science][Medline]
- Ayensa C. Diaz de Otazu R, Cia JM. Carbimazole-induced cholestatic hepatitis. Arch Intern Med 1986; 146: 1455.
- Chan AO, Ng IO, Lam SM, Shek TW, Lai CL. Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment for thyrotoxicosis. Hong Kong Med J 2003; 9: 37780.[Medline]doi:10.1093/ageing/afj068
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||